- November 2013
Highlights of the European Cancer Congress - cancer society presidents give their view.
- October 2013
Richard Schilsky on the changes needed as personalised medicine enters the clinic.
- September 2013
A new advance in immunotherapy is discussed by Jean-Charles Soria and Caroline Robert.
- July/August 2013
EORTC President Roger Stupp on challenges for clinical trials research.
- June 2013
A look ahead to the European Cancer Congress in Amsterdam in September.
- May 2013
Vincenzo Valentini explores the themes of the 2013 ESTRO forum.
- April 2013
Discussing cancer in an ageing population.
- March 2013
Richard Sullivan on global issues in childhood cancer.
- February 2013
How to write a paper that will be cited 12,000 times.
- January 2013
What predictions do oncologists have for the coming year?
EJC News Focus – July/August 2013
Good times and bad for clinical trials research
Functional imaging and other new technologies are revolutionising the landscape for cancer research. The knowledge imparted by these techniques – from genetics, epigenetics, proteomics and so on – should mean that we're entering a new phase in our understanding and therefore treatment of the disease.
Yet many of the same old obstacles between lab and clinic remain. Clinical trials research is still dogged by regulatory issues, funding is a perennial problem, agreement on data protection has yet to be reached.
EORTC President Roger Stupp calls for the patient's point of view to move centre stage. While rarified discussions and debates take place, patients are waiting for clinical trials to be set up and for results to be integrated into clinical practice, he says. Here, he tells Helen Saul that speedy activation of trials is needed, as is funding for academic trials and, overall, a common sense approach which would allow the questions most relevant to patients, to be addressed.